The verdict
Our read at a glance.
Whether sermorelin's GH-releasing pharmacology and discontinued approved use support the current anti-aging, body-composition, and wellness claims made for compounded sermorelin.
- The signal
- Sermorelin reliably stimulates growth hormone release in the short term, and older studies supported its use in growth hormone deficiency. Evidence for the modern anti-aging, body-composition, and longevity claims is limited, and there is no current approved product for those uses.
- The unknown
- Whether raising growth hormone with sermorelin produces meaningful long-term benefits or risks in healthy adults, and how much compounded product quality and identity vary.
- Our read
- Real GH-axis pharmacology, but not an approved anti-aging drug. Sermorelin does raise growth hormone, yet its modern wellness claims rest on thin evidence and compounded products, so the historical approval should not be read as endorsement of today's uses.
The mechanism
How it works.
Sermorelin is the first 29 amino acids of growth hormone-releasing hormone, the part of the natural hormone that carries its activity. It binds the GHRH receptor on the pituitary and prompts it to release growth hormone in natural-looking pulses, which then raises IGF-1 in the liver and other tissues. Because it works one step upstream of the pituitary rather than replacing growth hormone directly, its short-term GH-releasing action is well established, but whether that translates into meaningful anti-aging or body-composition benefits in healthy adults has not been shown.
Safety & regulatory boundary
The consequential part.
The original Geref product was discontinued, so current sermorelin is typically compounded or research-labeled rather than an FDA-approved product. Raising growth hormone is not free of risk, and compounded products carry quality and identity concerns. Sermorelin should not be treated as an approved anti-aging drug, and its GH-axis pharmacology does not validate longevity or performance claims.
What's next
What we're watching.
Any modern controlled trials in healthy adults, FDA actions on compounded GH-axis peptides, and product-identity and quality findings.
Context
Why this is discussed.
Sermorelin is marketed by anti-aging and hormone clinics as a gentler way to raise growth hormone, which keeps interest high even though its original approved product is no longer sold.
The evidence base
20 cited references.
Registered trials8
ClinicalTrials.gov · PHASE4 · TERMINATED · 2018-02-07
ClinicalTrials.gov · PHASE2 · RECRUITING · 2025-07-10
ClinicalTrials.gov · PHASE2 · RECRUITING · 2026-02-02
ClinicalTrials.gov · PHASE2 · COMPLETED · 2019-01-17
ClinicalTrials.gov · PHASE4 · RECRUITING · 2025-06-01
ClinicalTrials.gov · PHASE4 · TERMINATED · 2007-02
ClinicalTrials.gov · PHASE3 · COMPLETED · 2007-08
ClinicalTrials.gov · COMPLETED · 2006-09
Indexed literature (PubMed)12
Rahman OF et al. · J Am Acad Orthop Surg Glob Res Rev · 2026
Sinha DK et al. · Transl Androl Urol · 2020
Esposito P et al. · Adv Drug Deliv Rev · 2003
Grossman A et al. · Clin Endocrinol Metab · 1986
Mendias CL et al. · Sports Med · 2026
Xu Y et al. · J Int Med Res · 2012
Barkan A · Endocrinology · 1997
Costoya J et al. · Rev Endocr Metab Disord · 2025
Byrnes ME · Methods Mol Biol · 1994
Trainer PJ et al. · Clin Endocrinol (Oxf) · 1999
Neyzi O et al. · Acta Paediatr Suppl · 1993
Keep reading